Skip to main content

Table 5 Compilation of the antigen-specific response analysis

From: Differential cellular recognition pattern to M. tuberculosis targets defined by IFN-γ and IL-17 production in blood from TB + patients from Honduras as compared to health care workers: TB and immune responses in patients from Honduras

Antigen

Group 1

Group 2

Group 3

 

IFN-γ (%)

IL-17 (%)

IFN-γ (%)

IL-17 (%)

IFN-γ (%)

IL-17 (%)

Rv0447c

10/38 (26)

10/38 (26)

24/81 (30)

17/81 (21)

12/29 (41)

11/29 (38)

Rv2940c

3/38 (8)

 

8/81 (10)

 

3/29 (10)

 

Rv3347c

5/38 (13)

 

12/81 (15)

 

12/29 (41)

 

Rv2453c

4/38 (11)

 

11/81 (14)

 

9/29 (31)

 

Rv1886c

14/38 (37)

10/38 (26)

37/81 (46)

27/81 (33)

15/29 (52)

14/29 (48)

Rv1690

6/38 (16)

 

18/81 (22)

 

8/29 (28)

 

Rv3019c

8/38 (21)

10/38 (26)

29/81 (36)

37/81 (46)

9/29 (31)

16/29 (55)

Rv2957

7/38 (18)

11/38 (29)

30/81 (37)

33/81 (41)

11/29 (38)

12/29 (41)

Rv1085c

6/38 (16)

 

11/81 (14)

 

4/29 (14)

 

Rv0066c

3/38 (8)

 

14/81 (17)

 

4/29 (14)

 

Rv2958c

4/38 (11)

14/38 (37)

10/81 (12)

31/81 (38)

7/29 (24)

13/29 (45)

Rv2962c

3/38 (8)

10/38 (26)

10/81 (12)

32/81 (40)

8/29 (28)

15/29 (28)

Rv1886c

12/25(48)

12/25 (48)

40/65 (62)

47/65 (72)

11/17 (65)

15/17 (88)

Rv3804c

15/25 (60)

15/25 (60)

40/65 (62)

44/65 (68)

12/17 (71)

12/17 (71)

Rv3874

13/20 (65)

8/20 (40)

32/48 (67)

25/48 (52)

13/14 (93)

7/14 (50)

Rv3875

9/20 (45)

8/20 (40)

24/48 (50)

11/48 (23)

6/14 (43)

5/14 (36)

Rv0288 pep

3/11 (27)

 

3/21 (14)

 

0/3 (0)

 

Rv3804c/Rv1886c

3/11 (27)

 

3/21 (14)

 

0/3 (0)

 

Rv3875/3874

7/9 (78)

 

6/21 (29)

 

0/5 (0)

 

Rv0754

3/5 (60)

1/5 (20)

1/17 (6)

5/17 (29)

1/3 (33)

3/3 (100)

Rv0978

2/5 (40)

0/5 (0)

4/17 (24)

5/17 (29)

0/3 (0)

2/3 (66)

Rv1917

2/5 (40)

1/5 (20)

2/17 (12)

7/17 (41)

0/3 (0)

3/3 (100)

Rv0288

1/5 (20)

1/5 (20)

1/17 (6)

6/17 (35)

0/3 (0)

2/3 (66)

  1. Group 1, TB + patients, group 2, TB- other pulmonary diseases, group 3, frequent M.tb exposure, yet clinically healthy.